Featured Research

from universities, journals, and other organizations

More Than Half Of Relapsed CLL Patients Respond To Two Biologics With Chemotherapy

Date:
December 16, 2004
Source:
University Of Texas M. D. Anderson Cancer Center
Summary:
Combining two biologic agents with chemotherapy forms a potent drug regimen that is showing promise in treating patients who have relapsed with the most common kind of leukemia, chronic lymphocytic leukemia (CLL), researchers from The University of Texas M. D. Anderson Cancer Center report at the annual meeting of the American Society of Hematology (ASH).

SAN DIEGO - Combining two biologic agents with chemotherapy forms a potent drug regimen that is showing promise in treating patients who have relapsed with the most common kind of leukemia, chronic lymphocytic leukemia (CLL), researchers from The University of Texas M. D. Anderson Cancer Center report at the annual meeting of the American Society of Hematology (ASH).

Related Articles


The researchers combined two different monoclonal antibodies, alemtuzumab (Campath-1H) and rituximab (Rituxan) with the chemotherapy drugs cyclophosphamide and fludarabine. The combination is referred to as CFAR. Of 31 currently evaluable patients, 7 (23 percent) achieved complete remission, meaning no evidence of CLL remains, and the amount of leukemia in 11 patients (35 percent) has been reduced by at least half, says William Wierda, M.D., Ph.D., assistant professor of medicine in the Department of Leukemia.

"An overall response rate so far of 55 percent is very encouraging in this heavily pretreated population of patients that had limited treatment options," he says.

This study follows one reported by Wierda at last year's ASH meeting in which 143 less heavily pretreated patients were treated with rituximab, cyclophosphamide and fludarabine. This combination produced a response rate of 72 percent, of which 28 percent of patients achieved complete response remission. This complete remission rate was much higher than groups treated with either chemotherapy alone, or in combination.

Wierda and his group thought about adding alemtuzumab to the combination because of the synergistic activity of FCR and report that fludarabine combined with alemtuzumab had activity in patients that were resistant to both these agents. Alemtuzumab targets CD52, a protein expressed on the surface of leukemia cells. Rituximab, approved for use in follicular non-Hodgkin's lymphoma, targets CD20, also a cell surface protein on leukemia cells.

In the current trial, which is ongoing, patients have not experienced serious toxicity or early death, and Wierda expects the number of responders to increase with continued enrollment of less heavily pretreated patients. About half of the patients treated with CFAR had previously received FCR. "Had these patients been treated again with FCR,the response rate would not have reached that achieved with CFAR," he says.


Story Source:

The above story is based on materials provided by University Of Texas M. D. Anderson Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Texas M. D. Anderson Cancer Center. "More Than Half Of Relapsed CLL Patients Respond To Two Biologics With Chemotherapy." ScienceDaily. ScienceDaily, 16 December 2004. <www.sciencedaily.com/releases/2004/12/041206205625.htm>.
University Of Texas M. D. Anderson Cancer Center. (2004, December 16). More Than Half Of Relapsed CLL Patients Respond To Two Biologics With Chemotherapy. ScienceDaily. Retrieved December 18, 2014 from www.sciencedaily.com/releases/2004/12/041206205625.htm
University Of Texas M. D. Anderson Cancer Center. "More Than Half Of Relapsed CLL Patients Respond To Two Biologics With Chemotherapy." ScienceDaily. www.sciencedaily.com/releases/2004/12/041206205625.htm (accessed December 18, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, December 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Kids Die While Under Protective Services

Kids Die While Under Protective Services

AP (Dec. 18, 2014) As part of a six-month investigation of child maltreatment deaths, the AP found that hundreds of deaths from horrific abuse and neglect could have been prevented. AP's Haven Daley reports. (Dec. 18) Video provided by AP
Powered by NewsLook.com
UN: Up to One Million Facing Hunger in Ebola-Hit Countries

UN: Up to One Million Facing Hunger in Ebola-Hit Countries

AFP (Dec. 17, 2014) Border closures, quarantines and crop losses in West African nations battling the Ebola virus could lead to as many as one million people going hungry, UN food agencies said on Wednesday. Duration: 00:52 Video provided by AFP
Powered by NewsLook.com
When You Lose Weight, This Is Where The Fat Goes

When You Lose Weight, This Is Where The Fat Goes

Newsy (Dec. 17, 2014) Can fat disappear into thin air? New research finds that during weight loss, over 80 percent of a person's fat molecules escape through the lungs. Video provided by Newsy
Powered by NewsLook.com
Why Your Boss Should Let You Sleep In

Why Your Boss Should Let You Sleep In

Newsy (Dec. 17, 2014) According to research out of the University of Pennsylvania, waking up for work is the biggest factor that causes Americans to lose sleep. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins